Description
Bayrocin 150 Mg Tablet for Dogs – Broad Spectrum Antibiotic
Bayrocin 150 Mg Tablet is a powerful veterinary antibiotic containing Enrofloxacin, a fluoroquinolone antibacterial agent widely prescribed for dogs. Manufactured by Virbac, Bayrocin is trusted by veterinarians for treating a wide range of bacterial infections effectively and safely.
This high-strength 150 mg formulation is especially suitable for medium to large breed dogs suffering from moderate to severe bacterial infections.
Key Benefits of Bayrocin 150 Mg Tablet
- Broad-spectrum antibacterial action
- Effective against Gram-positive and Gram-negative bacteria
- Helps treat skin, urinary, and respiratory infections
- Fast absorption and quick therapeutic response
- Vet-recommended antibiotic for dogs
- Convenient oral tablet form
Uses of Bayrocin 150 Mg Tablet for Dogs
Bayrocin 150 Mg is commonly prescribed for:
- Pyoderma (bacterial skin infections)
- Infected wounds and abscesses
- Urinary Tract Infections (UTIs)
- Respiratory tract infections
- Ear infections (bacterial otitis)
- Gastrointestinal bacterial infections
Enrofloxacin works by inhibiting bacterial DNA synthesis, preventing the growth and multiplication of infection-causing bacteria.
Dosage & Administration
- Use strictly as prescribed by your veterinarian.
- Dosage depends on your dog’s body weight and severity of infection.
- Complete the full prescribed course to prevent antibiotic resistance.
Do not self-medicate your pet without professional veterinary guidance.
Precautions
- Not recommended for growing puppies (especially large breeds).
- Use cautiously in dogs with seizure disorders.
- Avoid use in pregnant or lactating dogs unless advised by a veterinarian.
- Store in a cool, dry place away from sunlight.
Why Buy Bayrocin 150 Mg Tablet from Pettivo?
At Pettivo, we offer 100% genuine veterinary medicines at competitive prices. Enjoy secure ordering, quick delivery, and trusted pet healthcare products delivered to your doorstep across India.




Reviews
There are no reviews yet.